JAMA: preliminary communication; original investigation; editorial
Published January 15, 2019  11:00 ET (News release from JAMA)
Researchers compared the effect of a stem cell transplant using a lower-dose, short course of more tolerable immune-specific chemotherapy and antibodies to suppress the immune system versus continuing disease-modifying therapy in 110 patients with relapsing–remitting multiple sclerosis. The stem cell transplant performed better than continued drug therapy for patients with frequent relapses and moderate disability

Corresponding authors: preliminary communication – Richard Burt, Northwestern University, Chicago - rburt@northwestern.edu; original investigation: Tomas Kalincik, Royal Melbourne Hospital, Australia – tomas.kalincik@unimelb.edu.au; editorial: Harold Atkins, Ottawa Hospital Research Institute, University of Ottawa – hatkins@ohri.ca
(NOTE: No Canadians on these papers, but they corroborate results published by Harold Atkins and Mark Freedman, of The Ottawa Hospital Research Institute, in 2016. Atkins provides the editorial noted above.)